LABORATORY RESEARCH NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis To examine the impact of NCOA1 overexpression on morphogenesis and carcinogenesis in the mammary gland (MG), researchers generated MMTV-hNCOA1 transgenic mice. In the context of two distinct transgenic models of breast cancer, NCOA1 overexpression did not affect the morphology or tumor forming capability of MG epithelial cells. [Cancer Res] Abstract Human Rhomboid Family-1 Suppresses Oxygen-Independent Degradation of Hypoxia-Inducible Factor-1α in Breast Cancer Researchers report here that rhomboid family-1 expression in breast cancer is highly elevated and is strongly correlated with escalated disease progression, metastasis, poor prognosis, and poor response to chemotherapy. [Cancer Res] Abstract SIP1/NHERF2 Enhances Estrogen Receptor Alpha Transactivation in Breast Cancer Cells Investigators identified the protein Na+/H+ Exchanger Regulatory Factor 2 (NHERF2) as an estrogen receptor alpha (ERα)-associated coactivator that interacts predominantly with the AF-1 domain of the nuclear receptor. Overexpression of NHERF2 in breast cancer MCF7 cells produced an increase in ERα transactivation. [Nucleic Acids Res] Full Article The Sodium Channel β1 Subunit Mediates Outgrowth of Neurite-Like Processes on Breast Cancer Cells and Promotes Tumor Growth and Metastasis Scientists found that SCN1B mRNA/β1 protein were up-regulated in breast cancer (BCa) specimens, compared with normal breast tissue. β1 upregulation substantially increased tumor growth and metastasis in a xenograft model of BCa. [Int J Cancer] Full Article | Press Release Induced Pluripotent Stem Cell-Derived Neural Stem Cells Transduced with Baculovirus Encoding CD40 Ligand for Immunogene Therapy in Mouse Models of Breast Cancer Neural stem cells were derived from human induced pluripotent stem cells, transduced in vitro with a baculoviral vector encoding CD40 ligand, and intravenously injected into mice with orthotopic and metastatic breast cancers in immunocompetent mice. [Hum Gene Ther] Abstract Dioscin Induces Caspase-Independent Apoptosis through Activation of Apoptosis-Inducing Factor in Breast Cancer Cells Scientists found that dioscin treatment induced cell death in dose-dependent manner in breast cancer cells such as MDA-MB-231, MDA-MB-453, and T47D cells. Dioscin decreased expressions of Bcl-2 and cIAP-1 proteins, which were down-regulated at the transcriptional level. [Apoptosis] Abstract Notch-1 Signaling Promotes the Malignant Features of Human Breast Cancer through NF-κB Activation Using multiple cellular and molecular approaches, researchers demonstrated that activation of Notch-1 signaling pathway promoted the malignant behaviors of MDA-MB-231 cells such as increased cell proliferation, colony formation, adhesion, migration, and invasion, and inhibited apoptosis; whereas deactivation of this signaling pathway led to the reversal of the aforementioned malignant cellular behaviors. [PLoS One] Full Article Down-Regulation of Asparagine Synthetase Induces Cell Cycle Arrest and Inhibits Cell Proliferation of Breast Cancer Investigators employed RNA interference as an efficient tool to silence endogenous asparagine synthetase (ASNS) expression in breast cancer cell lines. The relationship between ASNS expression and breast cancer cell growth was investigated, and the therapeutic value of ASNS in breast cancer was further evaluated. [Chem Biol Drug Des] Abstract CLINICAL RESEARCH US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status Joint hormone receptor/human epidermal growth factor 2 (HER2) status distributions by age, race/ethnicity, county-level poverty, registry, stage, Bloom-Richardson grade, tumor size, and nodal status were evaluated using multivariable adjusted polytomous logistic regression. [J Natl Cancer Inst] Abstract Population Pharmacometric Analyses of Eribulin in Patients with Locally Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes Pharmacometric investigation of eribulin was undertaken in patients with metastatic breast cancer and other advanced solid tumors. A population pharmacokinetic model used data combined from seven Phase I studies, and one Phase II, and one Phase III study. [J Clin Pharmacol] Abstract |